6,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one | 61051-68-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 6,8-Dihydroxy-3,4-dihydronaphthalin-1(2H)-on-3；6,8-Dihydroxy-3,4-dihydronaphthalin-1(2H)-on；6,8-Dihydroxy-1-tetralon；6,8-dihydroxy-1-tetralone；6,8-dihydroxy-3,4-dihydro-2H-naphthalen-1-one
• CAS: 61051-68-1
• 化学式: C₁₀H₁₀O₃
• 分子量: 178.188
• InChiKey: XWOTWRLMRAPMBE-UHFFFAOYSA-N

物化性质

• 沸点：
  404.2±25.0 °C(Predicted)
• 密度：
  1.374±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one 在 碘 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 以74 %的产率得到6,8-dihydroxy-7-iodo-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  对映选择性转移氢化环加成解锁了 SF2446 B3 的全合成：阿尼霉素和 SF2446 II 型聚酮化合物抗生素的糖苷配基

  摘要：

  描述了芳霉素/SF2446 II 型聚酮化合物的首次全合成和结构验证，以 SF2446 B3 的从头构建为代表，SF2446 B3 是该 II 型聚酮化合物家族共有的糖苷配基。钌催化的α-酮醇-苯并环丁烯酮[4 + 2]环加成通过连续的立体消融-立体再生发生，影响双动态动力学不对称转变，其中两种外消旋起始材料结合形成拥挤的安古环素海湾区域，并控制区域、非对映体- 和对映选择性。这项工作代表了转移氢化环加成和对映选择性分子间金属催化 C-C 键活化在靶向合成中的首次应用。

  DOI：

  10.1021/jacs.3c06225
• 作为产物：
  描述：

  6,8-dimethoxy-3,4-dihydro-2H-naphthalen-1-one 在 氢溴酸 、 溶剂黄146 作用下， 反应 48.0h， 以88%的产率得到6,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  作为 Hsp90 抑制剂的双环 radester 类似物的设计、合成和生物活性

  摘要：

  已经合成并评估了双环 radester 类似物的 Hsp90 抑制活性。这些类似物诱导 Hsp90 依赖性客户蛋白的浓度依赖性降解，六元双环类似物与五元对应物相比表现出更高的活性。

  DOI：

  10.1016/j.bmcl.2009.10.091

文献信息

• 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
  申请人：Pfizer Inc.

  公开号：US04188495A1

  公开（公告）日：1980-02-12

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, benzyl, benzoyl, alkanoyl of 1 to 5 carbon atoms or --CO--(CH.sub.2).sub.p --NR'R" wherein p is 0 or an integer from 1 to 4; each of R' and R" when taken individually is hydrogen or alkyl of 1 to 4 carbon atoms; R' and R" when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring selected from piperidino, pyrollo, pyrrolidino, morpholino and N-alkylpiperazino having from 1 to 4 carbon atoms in the alkyl group; R.sub.2 is selected from hydrogen, alkanoyl of 1 to 6 carbon atoms and benzoyl; R.sub.3 is selected from hydrogen, methyl and ethyl; R.sub.4 is selected from hydrogen, alkyl of 1 to 6 carbon atoms and benzyl; Z is selected from: (a) alkylene having from one to nine carbon atoms; (b) --(alk.sub.1).sub.m --X--(alk.sub.2).sub.n -- wherein each of (alk.sub.1) and (alk.sub.2) is alkylene having from 1 to 9 carbon atoms, with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than 9; m and n are each 0 or 1; X is selected from O, S, SO, and SO.sub.2 ; and W is selected from hydrogen, methyl, pyridyl, piperidyl, phenyl, monochlorophenyl, monofluorophenyl and ##STR2## wherein W.sub.1 is selected from hydrogen, phenyl, monochlorophenyl and monofluorophenyl; a is an integer from 1 to 5 and b is 0 or an integer from 1 to 4, with the proviso that the sum of a and b is not greater than 5. Compounds I and II are useful as analgesics. Compound III is useful as an intermediate for the preparation of Compounds I and II. Intermediates for the preparation of I, II and III are disclosed. A process for the use of compounds I and II to produce analgesia is also described.

  化合物的式子为##STR1##其中R.sub.1是氢，苄基，苯甲酰，1至5个碳原子的脂肪酰基或--CO--(CH.sub.2).sub.p --NR'R"，其中p为0或1至4的整数; R'和R"分别为氢或1至4个碳原子的烷基; 当R'和R"与它们所连接的氮一起形成5-或6-成员的杂环环时，所选的杂环环从哌啶，吡咯，吡咯烷，吗啉和N-烷基哌嗪中选择，其烷基中含有1至4个碳原子; R.sub.2从氢，1至6个碳原子的脂肪酰基和苯甲酰中选择; R.sub.3从氢，甲基和乙基中选择; R.sub.4从氢，1至6个碳原子的烷基和苄基中选择; Z从以下选取：(a)含有1至9个碳原子的烷基;(b)--(alk.sub.1).sub.m --X--(alk.sub.2).sub.n --其中(alk.sub.1)和(alk.sub.2)分别是含有1至9个碳原子的烷基，但(alk.sub.1)加(alk.sub.2)中碳原子的总和不大于9; m和n均为0或1; X从O，S，SO和SO.sub.2中选择; W从氢，甲基，吡啶基，哌啶基，苯基，单氯苯基，单氟苯基和##STR2##其中W.sub.1从氢，苯基，单氯苯基和单氟苯基中选择; a为1至5的整数，b为0或1至4的整数，但a和b的和不大于5。化合物I和II在镇痛方面有用。化合物III在制备化合物I和II的中间体方面有用。公开了制备I，II和III的中间体。还描述了使用化合物I和II产生镇痛的过程。
• 1,9-Dihydroxyoctahydrophenanthrenes
  申请人：Pfizer Inc.

  公开号：US04237133A1

  公开（公告）日：1980-12-02

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, benzyl, benzoyl, alkanoyl of 1 to 5 carbon atoms or --CO--(CH.sub.2).sub.p --NR'R" wherein p is 0 or an integer from 1 to 4; each of R' and R" when taken individually is hydrogen or alkyl of 1 to 4 carbon atoms; R' and R" when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring selected from piperidino, pyrollo, pyrrolidino, morpholino and N-alkylpiperazino having from 1 to 4 carbon atoms in the alkyl group; R.sub.2 is selected from hydrogen, alkanoyl of 1 to 6 carbon atoms and benzoyl; R.sub.3 is selected from hydrogen, methyl and ethyl; R.sub.4 is selected from hydrogen, alkyl of 1 to 6 carbon atoms and benzyl; Z is selected from: (a) alkylene having from one to nine carbon atoms; (b) --(alk.sub.1).sub.m --X--(alk.sub.2).sub.n -- wherein each of (alk.sub.1) and (alk.sub.2)is alkylene having from 1 to 9 carbon atoms, with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than 9; m and n are each 0 or 1; X is selected from O, S, SO and SO.sub.2 ; and W is selected from hydrogen, methyl, pyridyl, piperidyl, phenyl, monochlorophenyl, monofluorophenyl and ##STR2## wherein W.sub.1 is selected from hydrogen, phenyl, monochlorophenyl and monofluorophenyl; a is an integer from 1 to 5 and b is 0 or an integer from 1 to 4, with the proviso that the sum of a and b is not greater than 5. Compounds I and II are useful as analgesics. Compound III is useful as an intermediate for the preparation of Compounds I and II. Intermediates for the preparation of I, II and III are disclosed. A process for the use of compounds I and II to produce analgesia is also described.

  化合物的公式为##STR1##其中R.sub.1为氢，苄基，苯甲酰基，1至5个碳原子的脂肪酰基或--CO--(CH.sub.2).sub.p --NR'R"，其中p为0或1至4的整数；当R'和R"分别单独取时，它们是氢或1至4个碳原子的烷基；当R'和R"与它们结合的氮一起形成5-或6-成员的杂环环，所述杂环环被选择自哌啶，吡咯，吡咯烷，吗啉和N-烷基哌嗪，所述烷基中有1至4个碳原子；R.sub.2被选择自氢，1至6个碳原子的脂肪酰基和苯甲酰基；R.sub.3被选择自氢，甲基和乙基；R.sub.4被选择自氢，1至6个碳原子的烷基和苄基；Z被选择自：(a)有1至9个碳原子的烷基；(b)--(alk.sub.1).sub.m --X--(alk.sub.2).sub.n --其中(alk.sub.1)和(alk.sub.2)分别为有1至9个碳原子的烷基，但是(alk.sub.1)加上(alk.sub.2)的碳原子总和不大于9；m和n均为0或1；X被选择自O、S、SO和SO.sub.2；W被选择自氢，甲基，吡啶基，哌啶基，苯基，单氯苯基，单氟苯基和##STR2##其中W.sub.1被选择自氢，苯基，单氯苯基和单氟苯基；a为1至5的整数，b为0或1至4的整数，但是a和b的总和不大于5。化合物I和II有用作镇痛剂。化合物III有用作化合物I和II的中间体。公开了制备I、II和III的中间体。还描述了使用化合物I和II产生镇痛作用的过程。
• Intermediates to 1,9-dihydroxyoctahydrophenanthrenes
  申请人：Pfizer Inc.

  公开号：US04310668A1

  公开（公告）日：1982-01-12

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, benzyl, benzoyl, alkanoyl of 1 to 5 carbon atoms or --CO--(CH.sub.2).sub.p --NR'R" wherein p is 0 or an integer from 1 to 4; each of R' and R" when taken individually is hydrogen or alkyl of 1 to 4 carbon atoms; R' and R" when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring selected from piperidino, pyrrolo, pyrrolidino, morpholino and N-alkylpiperazino having from 1 to 4 carbon atoms in the alkyl group; R.sub.2 is selected from hydrogen, alkanoyl of 1 to 6 carbon atoms and benzoyl; R.sub.3 is selected from hydrogen, methyl and ethyl; R.sub.4 is selected from hydrogen, alkyl of 1 to 6 carbon atoms and benzyl; Z is selected from: (a) alkylene having from one to nine carbon atoms; (b) --(alk.sub.1).sub.m --X--(alk.sub.2).sub.n -- wherein each of (alk.sub.1) and (alk.sub.2) is alkylene having from 1 to 9 carbon atoms, with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than 9; m and n are each 0 or 1; X is selected from O, S, SO and SO.sub.2 ; and W is selected from hydrogen, methyl, pyridyl, piperidyl, phenyl, monochlorophenyl, monofluorophenyl and ##STR2## wherein W.sub.1 is selected from hydrogen, phenyl, monochlorophenyl and monofluorophenyl; a is an integer from 1 to 5 and b is 0 or an integer from 1 to 4, with the proviso that the sum of a and b is not greater than 5. Compounds I and II are useful as analgesics. Compound III is useful as an intermediate for the preparation of Compounds I and II. Intermediates for the preparation of I, II and III are disclosed. A process for the use of compounds I and II to produce analgesia is also described.

  化合物的公式为 ##STR1## 其中 R.sub.1 是氢，苄基，苯甲酰基，1至5个碳原子的脂肪酰基或--CO--(CH.sub.2).sub.p --NR'R"，其中p为0或1至4的整数; 当R'和R"分别为氢或1至4个碳原子的烷基时; 当R'和R"与它们所连接的氮一起形成选择自哌啶，吡咯，吡咯烷，吗啉和N-烷基哌嗪的5或6元杂环环；R.sub.2 选择自氢，1至6个碳原子的脂肪酰基和苯甲酰基；R.sub.3 选择自氢，甲基和乙基；R.sub.4 选择自氢，1至6个碳原子的烷基和苄基；Z选择自：(a) 1至9个碳原子的烷基；(b) --(alk.sub.1).sub.m --X--(alk.sub.2).sub.n --其中每个(alk.sub.1)和(alk.sub.2)是1至9个碳原子的烷基，但满足(alk.sub.1)加(alk.sub.2)的碳原子总数不大于9；m和n各自为0或1；X选择自O，S，SO和SO.sub.2；W选择自氢，甲基，吡啶基，哌啶基，苯基，单氯苯基，单氟苯基和 ##STR2## 其中W.sub.1选择自氢，苯基，单氯苯基和单氟苯基；a为1至5的整数，b为0或1至4的整数，但满足a和b的和不大于5。化合物I和II可用作镇痛剂。化合物III可用作制备化合物I和II的中间体。还公开了制备I，II和III的中间体。还描述了使用化合物I和II产生镇痛作用的过程。
• US4188495A
  申请人：——

  公开号：US4188495A

  公开（公告）日：1980-02-12
• US4237133A
  申请人：——

  公开号：US4237133A

  公开（公告）日：1980-12-02